Abstract
Trastuzumab deruxtecan (T-DXd) has been approved for metastatic HER2-positive gastric cancer (HER2+ mGC) since July 2022 in France, through an accelerated approval. This study aims to evaluate its real-world use. We characterized T-DXd users treated for HER2+ mGC using data from the French National Health Insurance. The cohort included 196 patients, mostly men (78.1%), with a median age of 65 years. Median overall survival reached 7.7 months (95% CI: 6.2-9.0). Patients treated with T-DXd for HER2+ mGC in the real-world showed lower outcomes than those in pivotal clinical trials, consistent with previous reports on accelerated approvals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
